It was suggested that the TBX-3 expression levels in endothelial cells may be regulated by SIRT1; as the genetic knockdown of these genes resulted in partial or complete phenotype reversal, it could be suggested that endothelium-targeted TBX-3 therapy may serve as a therapeutic option for regulating diabetes-associated co-morbidities arising from endothelial dysfunction. This evidence concerns the gene TBX3 and endothelial dysfunction.